At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 1.26: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.11BCNY317.14M · vs all stocks (USD)
Revenue (TTM)
421.93MCNY63.29M · vs all stocks (USD)
Profit Margin
-57.16%Beta
0.3070xvs all stocks
52-Week Change
-20.79%vs all stocks
Market Capitalization
2.11BCNY317.14M · vs all stocks (USD)
Enterprise Value
2.42BCNY363.28M · vs all stocks (USD)
Price to Sales (TTM)
5.17xPrice to Book (MRQ)
3.13xEnterprise to Revenue
5.74xEnterprise to EBITDA
-124.15xGross Margin
44.10%Profit Margin
-57.16%Operating Margin
-16.23%Return on Assets (TTM)
-2.68%Return on Equity (TTM)
-33.33%Revenue (TTM)
421.93MCNY63.29M · vs all stocks (USD)
Revenue per Share (TTM)
0.6710CNYUpdated Nov 19, 2026Quarterly Revenue Growth
-39.10%Gross Profit (TTM)
178.92MCNY26.84M · vs all stocks (USD)
EBITDA (TTM)
-19.51MCNY-2.93M · vs all stocks (USD)
Net Income (TTM)
-241.17MCNY-36.17M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-2.60%Operating Cash Flow (TTM)
63.57MCNY9.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-123.59MCNY-18.54M · vs all stocks (USD)
5-Year Average Dividend Yield
0.22%vs all stocks
Payout Ratio
64.52%Minority Interest (Equity)
-8.86MCNYFY2025 · Dec 31, 2025Revenue
545.50MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
285.78MCNYFY2025 · Dec 31, 2025Gross Profit
259.71MCNYFY2025 · Dec 31, 2025Operating Income
-93.21MCNY-13.98M · vs all stocks (USD)
Pre-tax Income
-337.03MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.05MCNYFY2025 · Dec 31, 2025Net Income
-346.08MCNYFY2025 · Dec 31, 2025EBIT
-326.04MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-79.92MCNYFY2025 · Dec 31, 2025Research & Development
23.44MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
234.56MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.27MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.70MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
10.99MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.5100CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.5100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
628.27MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
628.27MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-346.08MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
25.66MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-84.88MCNYFY2025 · Dec 31, 2025Free Cash Flow
-147.14MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
96.69MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-346.08MCNYFY2025 · Dec 31, 2025Other Non-cash Items
21.14MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
203.79MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
36.28MCNYFY2025 · Dec 31, 2025Capital Expenditures
-62.26MCNYFY2025 · Dec 31, 2025Net Acquisitions
920.67KCNYFY2025 · Dec 31, 2025Sale of Investments
201.97MCNYFY2025 · Dec 31, 2025Other Investing Activity
14.24MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
154.88MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
190.45MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-430.97MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-13.30MCNYFY2025 · Dec 31, 2025Other Financing Charges
-7.99MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-261.81MCNYFY2025 · Dec 31, 2025Shares Outstanding
623.72MSharesUpdated Nov 19, 2026Float Shares
486.93MSharesUpdated Nov 19, 2026% Held by Insiders
29.28%vs all stocks
% Held by Institutions
1.18%vs all stocks
Total Cash (MRQ)
88.23MCNY13.23M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1410CNYUpdated Nov 19, 2026Total Debt (MRQ)
341.30MCNY51.19M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4995xCurrent Ratio (MRQ)
0.7610xBook Value per Share (MRQ)
1.12CNYUpdated Nov 19, 2026Total Assets
1.39BCNY208.36M · vs all stocks (USD)
Total Current Assets
459.62MCNYFY2025 · Dec 31, 2025Total Liabilities
682.29MCNYFY2025 · Dec 31, 2025Total Non-current Assets
929.54MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
89.84MCNYFY2025 · Dec 31, 2025Total Current Liabilities
592.46MCNYFY2025 · Dec 31, 2025Cash
101.01MCNYFY2025 · Dec 31, 2025Cash Equivalents
22.27MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
123.28MCNYFY2025 · Dec 31, 2025Accounts Receivable
229.82MCNYFY2025 · Dec 31, 2025Inventory
55.76MCNYFY2025 · Dec 31, 2025Accounts Payable
145.22MCNYFY2025 · Dec 31, 2025Short-term Debt
312.44MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.27MCNYFY2025 · Dec 31, 2025Long-term Debt
50.85MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
4.79MCNYFY2025 · Dec 31, 2025Common Stock (Book)
623.72MCNYFY2025 · Dec 31, 2025Retained Earnings
-105.73MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
706.87MCNY106.02M · vs all stocks (USD)
52-Week Low
3.31CNYUpdated Nov 19, 202652-Week High
5.15CNYUpdated Nov 19, 202652-Week Change
-20.79%vs all stocks
Beta
0.3070xvs all stocks
50-Day MA
4.02CNYUpdated Nov 19, 2026200-Day MA
4.01CNYUpdated Nov 19, 2026Avg 10-Day Volume
15.66MSharesUpdated Nov 19, 2026Avg 30-Day Volume
25.72MSharesUpdated Nov 19, 2026Diluted EPS (TTM)
-0.3800CNYUpdated Nov 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.44Profit Margin: -0.57
Financial Health
Altman Z-Score 1.26: grey zoneSignificant
Altman Z-Score: 1.26
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Solara Active Pharma Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dishman Carbogen Amcis Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Green Cross Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cuorips Inc.
Tier 1ProductionApproval-Gated PipelineRule
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule